These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12562213)

  • 1. Predicting response to lithium in mood disorders: role of genetic polymorphisms.
    Serretti A; Artioli P
    Am J Pharmacogenomics; 2003; 3(1):17-30. PubMed ID: 12562213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium long-term treatment in mood disorders: clinical and genetic predictors.
    Serretti A
    Pharmacogenomics; 2002 Jan; 3(1):117-29. PubMed ID: 11966408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics in affective disorders.
    Serretti A; Lilli R; Smeraldi E
    Eur J Pharmacol; 2002 Mar; 438(3):117-28. PubMed ID: 11909602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predictors of prophylactic response to lithium].
    Rohayem J; Baylé JF; Richa S
    Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness.
    Steen VM; Løvlie R; Osher Y; Belmaker RH; Berle JO; Gulbrandsen AK
    Pharmacogenetics; 1998 Jun; 8(3):259-68. PubMed ID: 9682271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.
    Serretti A; Malitas PN; Mandelli L; Lorenzi C; Ploia C; Alevizos B; Nikolaou C; Boufidou F; Christodoulou GN; Smeraldi E
    Pharmacogenomics J; 2004; 4(4):267-73. PubMed ID: 15111989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium for maintenance treatment of mood disorders.
    Burgess S; Geddes J; Hawton K; Townsend E; Jamison K; Goodwin G
    Cochrane Database Syst Rev; 2001; (3):CD003013. PubMed ID: 11687035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
    Munch G; Godart N
    Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions.
    Lerer B; Macciardi F
    Int J Neuropsychopharmacol; 2002 Sep; 5(3):255-75. PubMed ID: 12366879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serotonin transporter gene and effectiveness of SSRIs.
    Serretti A; Kato M
    Expert Rev Neurother; 2008 Jan; 8(1):111-20. PubMed ID: 18088204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin transporter gene associated with lithium prophylaxis in mood disorders.
    Serretti A; Lilli R; Mandelli L; Lorenzi C; Smeraldi E
    Pharmacogenomics J; 2001; 1(1):71-7. PubMed ID: 11913731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic factors and treatment of mood disorders.
    Alda M
    Bipolar Disord; 2001 Dec; 3(6):318-24. PubMed ID: 11843781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants.
    Serretti A; Lorenzi C; Lilli R; Mandelli L; Pirovano A; Smeraldi E
    Am J Med Genet; 2002 May; 114(4):370-9. PubMed ID: 11992559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.
    Oedegaard KJ; Alda M; Anand A; Andreassen OA; Balaraman Y; Berrettini WH; Bhattacharjee A; Brennand KJ; Burdick KE; Calabrese JR; Calkin CV; Claasen A; Coryell WH; Craig D; DeModena A; Frye M; Gage FH; Gao K; Garnham J; Gershon E; Jakobsen P; Leckband SG; McCarthy MJ; McInnis MG; Maihofer AX; Mertens J; Morken G; Nievergelt CM; Nurnberger J; Pham S; Schoeyen H; Shekhtman T; Shilling PD; Szelinger S; Tarwater B; Yao J; Zandi PP; Kelsoe JR
    BMC Psychiatry; 2016 May; 16():129. PubMed ID: 27150464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of atypical antipsychotics in mood disorders.
    Yatham LN
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S9-14. PubMed ID: 12832944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments.
    Serretti A; Benedetti F; Zanardi R; Smeraldi E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1074-84. PubMed ID: 15939518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
    Lenox RH; McNamara RK; Watterson JM; Watson DG
    J Clin Psychiatry; 1996; 57 Suppl 13():23-31; discussion 32-3. PubMed ID: 8970502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodevelopment and mood stabilizers.
    Harwood AJ
    Curr Mol Med; 2003 Aug; 3(5):472-82. PubMed ID: 12943000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is a "mood stabilizer"? An evidence-based response.
    Bauer MS; Mitchner L
    Am J Psychiatry; 2004 Jan; 161(1):3-18. PubMed ID: 14702242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.